Abstract
Cardiovascular disease (CVD) is the leading cause of death among renal transplant recipients with a functioning transplant. The prevalence and severity of CVD in renal transplant recipients are related to numerous factors, most shared with the general population and others specific to transplant recipients, including effects of kidney dysfunction and immunosuppressive drugs. Modern immunosuppressive regimens have allowed a decrease in the dose of corticosteroids, which markedly increase cardio-vascular risk. However, each of the 3 agents commonly used as the base for immunosuppressive regimens, cyclosporine, tacrolimus, and sirolimus, may contribute significantly to 1 or more cardio-vascular risk factors that are already of substantial concern in this population. Cyclosporine has been associated with the greatest hypertensive effect; tacrolimus, with the greatest impact on diabetes and glycemic control; and sirolimus, with the greatest impact on lipid profiles. This review highlights the major causes of CVD in renal transplant recipients, with particular attention to hypertension, diabetes, and dyslipidemia, and evaluates the contribution of immunosuppressive agents to cardiovascular risk.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
